{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:43:24Z","timestamp":1761864204840,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.dld.2020.11.004","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T20:16:08Z","timestamp":1605903368000},"page":"258-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["When helping the minority of patients may hurt the majority: The case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring."],"prefix":"10.1016","volume":"53","author":[{"given":"C","family":"Tron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emeric","family":"Boisteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S Le","family":"Sourd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Li\u00e8vre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2020.11.004_bib0001","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/17425255.2018.1550484","article-title":"How can we best monitor 5-FU administration to maximize benefit to risk ratio?","volume":"14","author":"Goirand","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"unstructured":"European Medicine Agency. EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. 2020.","key":"10.1016\/j.dld.2020.11.004_bib0002"},{"key":"10.1016\/j.dld.2020.11.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-020-0962-z","article-title":"A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency","author":"Pallet","year":"2020","journal-title":"Br J Cancer"},{"unstructured":"ANSM, HAS, INCa. Recherche de d\u00e9ficit en dihydropyrimidine d\u00e9shydrogenase en vue de pr\u00e9venir certaines toxicit\u00e9s s\u00e9v\u00e8res survenant sous traitement comportant des fluoropyrimidines. (consulted the 17yh of july). 2018.","key":"10.1016\/j.dld.2020.11.004_bib0004"},{"key":"10.1016\/j.dld.2020.11.004_bib0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"[Dihydropyrimidine d\u00e9hydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks]","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.dld.2020.11.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000000768","article-title":"Phenotyping of uracil and 5-fluorouracil metabolism using LC-MS\/MS for prevention of toxicity and dose adjustment of fluoropyrimidines","author":"Tafzi","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dld.2020.11.004_bib0007","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt.1124","article-title":"Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy","volume":"105","author":"Beumer","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dld.2020.11.004_bib0008","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"},{"doi-asserted-by":"crossref","unstructured":"Adjei A.A., Reid J.M., Diasio R.B., Sloan J.A., Smith D.A., Rubin J., et al. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors 2002:9.","key":"10.1016\/j.dld.2020.11.004_bib0009","DOI":"10.1200\/JCO.2002.20.6.1683"},{"doi-asserted-by":"crossref","unstructured":"Beumer J.H., Boisdron-Celle M., Clarke W., Courtney J.B., Egorin M.J., Gamelin E., et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the olympus AU400 analyzer: therapeutic drug monitoring 2009;31:688\u201394. https:\/\/doi.org\/10.1097\/FTD.0b013e3181b9b8c0.","key":"10.1016\/j.dld.2020.11.004_bib0010","DOI":"10.1097\/FTD.0b013e3181b9b8c0"},{"key":"10.1016\/j.dld.2020.11.004_bib0011","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12885-020-06907-0","article-title":"DPD status and fluoropyrimidines-based treatment: high activity matters too","volume":"20","author":"Chamorey","year":"2020","journal-title":"BMC Cancer"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582031001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582031001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:15:19Z","timestamp":1761624919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086582031001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S159086582031001X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2020.11.004","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When helping the minority of patients may hurt the majority: The case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring.","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2020.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}